PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33230949-1	2021	The L-type amino acid transporter 1 (LAT1, SLC7A5) imports dietary amino acids and amino acid drugs (e.g. L-DOPA) into the brain, and it plays a role in cancer metabolism.	Levodopa	106-112	solute carrier family 7 member 5	Homo sapiens	4-35	
33933805-3	2021	The recognition and binding processes of LAT1-ligands, such as amino acids and clinically used small molecules, including l-dopa, gabapentin, and melphalan, are today well-known.	Levodopa	122-128	solute carrier family 7 member 5	Homo sapiens	41-45	
33230949-1	2021	The L-type amino acid transporter 1 (LAT1, SLC7A5) imports dietary amino acids and amino acid drugs (e.g. L-DOPA) into the brain, and it plays a role in cancer metabolism.	Levodopa	106-112	solute carrier family 7 member 5	Homo sapiens	37-41	
33230949-1	2021	The L-type amino acid transporter 1 (LAT1, SLC7A5) imports dietary amino acids and amino acid drugs (e.g. L-DOPA) into the brain, and it plays a role in cancer metabolism.	Levodopa	106-112	solute carrier family 7 member 5	Homo sapiens	43-49	
32377929-6	2020	Thus, the anti-parkinsonian drug, L-Dopa, the anti-cancer drug, melphalan and the anti-epileptic drug gabapentin, all used in clinical practice, utilize LAT1 to reach their target site.	Levodopa	34-40	solute carrier family 7 member 5	Homo sapiens	153-157	
33367937-8	2020	While the concept works to some extent, a lot of challenges have been encountered in terms of obtaining efficient inhibition while avoiding adverse effects.Some CNS drug compounds enter the brain via nutrient transport proteins, an example is the levodopa, a prodrug of Dopamine, which crosses the BBB via the large neutral amino acid transporter LAT1.	Levodopa	247-255	solute carrier family 7 member 5	Homo sapiens	347-351	
30867591-2	2019	LAT1, an antiporter of the amino acid-polyamine-organocation superfamily, also catalyses the permeation of thyroid hormones, pharmaceutical drugs, and hormone precursors such as L-3,4-dihydroxyphenylalanine across membranes2-6.	Levodopa	178-206	solute carrier family 7 member 5	Homo sapiens	0-4	
30055889-2	2018	The resulting prodrug, dopa-CBT, inhibited the uptake of the LAT1 substrate [14C]-l-leucine in LAT1-expressing MCF-7 cells with an IC50 value of 28 microM, which was 3.5-times lower than that of the gold standard for dopamine replacement therapy, l-dopa (IC50 ca.	Levodopa	247-253	solute carrier family 7 member 5	Homo sapiens	61-65	
30189294-3	2019	The drug L-DOPA efficiently and specifically crosses the BBB via the large neutral amino acid transporter (LAT)-1 protein to enter the brain.	Levodopa	9-15	solute carrier family 7 member 5	Homo sapiens	107-113	
20606323-6	2010	Our findings indicate that decreased LAT1 expression at the BBB in PD patients may adversely affect amino acid supply from the circulating blood and levodopa distribution into the brain.	Levodopa	149-157	solute carrier family 7 member 5	Homo sapiens	37-41	
28490336-9	2017	Gabapentin and L-dopa as the substrates of LAT1 competitively inhibited the uptake of [14C] L-citrulline.	Levodopa	15-21	solute carrier family 7 member 5	Homo sapiens	43-47	
27224648-2	2016	18F-FDOPA is a large neutral amino acid biochemically resembling endogenous L-DOPA and taken up by the L-type amino acid transporters (LAT1 and LAT2).	Levodopa	76-82	solute carrier family 7 member 5	Homo sapiens	135-139	
15351512-11	2004	Additional in-vitro studies using human LAT1 reveal a much lower affinity of FDOPA compared to OMFD or L-DOPA.	Levodopa	103-109	solute carrier family 7 member 5	Homo sapiens	40-44	
18656534-3	2008	Only a few drugs (less than 10) are substrates of LAT1 and LAT2, including L-DOPA, alpha-methyldopa, melphalan, and gabapentin.	Levodopa	75-81	solute carrier family 7 member 5	Homo sapiens	50-54